Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study

AIMS: Coronavirus disease 2019 (COVID‐19) is caused by a novel severe acute respiratory syndrome coronavirus 2. It can lead to multiorgan failure, including respiratory and cardiovascular decompensation, and kidney injury, with significant associated morbidity and mortality, particularly in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosiborod, Mikhail, Berwanger, Otavio, Koch, Gary G., Martinez, Felipe, Mukhtar, Omar, Verma, Subodh, Chopra, Vijay, Javaheri, Ali, Ambery, Philip, Gasparyan, Samvel B., Buenconsejo, Joan, Sjöström, C. David, Langkilde, Anna Maria, Oscarsson, Jan, Esterline, Russell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Clinical Trial Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049025/
https://www.ncbi.nlm.nih.gov/pubmed/33319454
http://dx.doi.org/10.1111/dom.14296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049025/
https://www.ncbi.nlm.nih.gov/pubmed/33319454
http://dx.doi.org/10.1111/dom.14296

Ejemplares similares